Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by ...

The pharmaceutical segment contributed Rs 6,503.63 crore to the quarterly revenue, reflecting an 8.5 per cent growth, while ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

Results: Cipla reported a 30.12% year-on-year increase in Q4FY25 net profit, reaching ₹1,221.84 crore, up from ₹939.04 crore.

Board of directors recommend a final dividend of ₹14 per equity share for FY25 and a special dividend of ₹3 per share ...

Pharma giant Cipla announced a significant 30 percent increase in consolidated net profit attributable to shareholders for ...

Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based ...

Along with the Q4 results, Cipla announced a final dividend of Rs 13 per equity share for the financial year 2025, and a ...

Cipla CEO says US order to lower drug prices won't impact Indian generic drugmakers. The order is likely to target branded ...

Cipla MD Umang Vohra assured that the US government's directive to lower prescription drug costs will not impact Indian ...